A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Sirolimus (Primary) ; Cancer vaccine NY-ESO-1; MIS 416
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 24 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 15 Aug 2017.
- 10 Jun 2017 Biomarkers information updated
- 31 May 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.